Jump to content

FERb 033

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 147.147.108.194 (talk) at 20:36, 23 October 2022 (Removing advertising). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

FERb 033
Identifiers
  • 2-Chloro-3′-fluoro-3,4′-dihydroxy-[1,1-biphenyl]-4-carboxaldehyde oxime
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H9ClFNO3
Molar mass281.67 g·mol−1
3D model (JSmol)
  • c1cc(c(cc1c2ccc(c(c2Cl)O)/C=N/O)F)O
  • InChI=1S/C13H9ClFNO3/c14-12-9(3-1-8(6-16-19)13(12)18)7-2-4-11(17)10(15)5-7/h1-6,17-19H/b16-6+
  • Key:LRRMQNGSYOUANY-OMCISZLKSA-N

FERb 033 is a synthetic, nonsteroidal estrogen that was synthesized in 2009 and is used in scientific research.[1][2] It is a potent and selective ERβ agonist (Ki = 7.1 nM, EC50 = 4.8 nM), with 62-fold selectivity for the ERβ over the ERα.[1][2]

See also

References

  1. ^ a b Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA, Macchia M (2009). "Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta". J. Med. Chem. 52 (3): 858–67. doi:10.1021/jm801458t. PMID 19128016.
  2. ^ a b Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR (2014). "ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer". BMC Cancer. 14: 749. doi:10.1186/1471-2407-14-749. PMC 4196114. PMID 25288324.{{cite journal}}: CS1 maint: unflagged free DOI (link)